Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wearable Devices Ltd. filings document its foreign private issuer reporting for AI-powered touchless sensing wearables, Mudra neural input products and software platforms for XR, mobile and AI applications. Form 6-K reports furnish product announcements, patent notices, financial results and updates on ai6 Labs, Mudra Experience Studio, Mudra Link and Mudra Band.
The filings also cover capital-structure and governance matters, including ordinary shares and tradable warrants, reverse share split disclosure, shareholder meeting results, compensation policy amendments, equity incentive plan share reserves, and incorporation by reference into Form S-8 and Form F-3 registration statements.
Wearable Devices Ltd. prospectus supplement discloses financing and capitalization details and highlights material risks. The company reported an explanatory paragraph in its interim financial statements expressing substantial doubt about its ability to continue as a going concern. The document lists multiple classes of potentially dilutive securities, including options, warrants, pre-funded warrants, RSUs and reserved shares, with explicit counts such as 3,322,000 Ordinary Shares subject to shareholder approval for warrants, 564,059 RSUs outstanding, 98,589 IPO warrants, and additional warrants exercisable at $4.00 and $6.00 for 1,000,000 and 670,000 shares respectively. A pro forma capitalization table shows total shareholders' equity increasing to $20,104 on a pro forma basis after recent issuances described, and the assumed offering price used for illustrative pro forma calculations is $5.37 per share. The supplement also outlines permitted offering and distribution methods, material terms for warrants and units, and estimated offering expenses including $15,000 legal fees and $3,000 accounting fees.
Wearable Devices Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners that allows it to sell, from time to time, up to $7,400,000 of its ordinary shares in an "at the market" offering. These shares will be issued under the company’s existing Form F-3 registration statement and related prospectus documents.
The company expects to use any proceeds from these share sales for working capital and general corporate purposes. It is not required to sell any shares, and the Sales Agent will act only on the company’s instructions while using commercially reasonable efforts to place the stock. A.G.P. will receive a commission equal to 3.0% of the aggregate gross proceeds from each sale, and the company will reimburse certain expenses and provide customary indemnification.
Wearable Devices Ltd., a foreign private issuer, submitted a Form 6-K to furnish the Notice of Meeting, Proxy Statement and Proxy Card for its Annual and Special General Meeting of Shareholders scheduled for October 24, 2025. Only shareholders of record holding ordinary shares at the close of business on September 26, 2024 are entitled to receive notice of, and vote at, the meeting in person or by proxy. The Form 6-K and its exhibit are also incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3.
Wearable Devices Ltd. filed a Form D for a new, non-public securities offering under Rule 506(b) seeking up to $4,020,000 in gross proceeds, with $0 sold to date and
Wearable Devices Ltd. filed a Form D to raise up to $4,000,000 under Regulation D, relying on Rule 506(b). The offering is for options/warrants and the securities issuable on exercise of those rights, with $0 sold to date and $4,000,000 remaining available. The company is incorporated in Israel and lists key executives including Asher Dahan (CEO & Chairman), CFO Tamar Fleisher, and other senior officers. The filing shows solicitation through A.G.P./Alliance Global Partners and reports $0 in sales commissions and finders fees and $0 of the offering proceeds proposed to be paid to named officers or directors. The minimum investment is listed as $0 and the issuer does not intend the offering to last more than one year.
Wearable Devices Ltd. (WLDS) prospectus supplement discloses capital structure changes, outstanding equity instruments, and a going-concern uncertainty. The company reports multiple classes of reserved and issuable Ordinary Shares (including options, warrants, RSUs and pre-funded warrants) totaling millions of potential shares that would dilute existing holders if issued. Pro forma adjustments reflect recent financings and a contemplated offering that raise net proceeds and increase pro forma net tangible book value per share from $1.67 to $1.91, and to $2.31 after this offering, with dilution per new investor estimated at $3.69 (61.48%). The filing lists specific reserved amounts (for example, 3,322,000 shares subject to shareholder approval and 564,059 RSUs) and describes distribution mechanics, underwriting limits, and legal/expense items.
Wearable Devices Ltd. entered into a Securities Purchase Agreement with a single institutional investor for a $4 million financing consisting of a registered direct offering and a concurrent private placement. The company is selling 440,000 ordinary shares at $6.00 per share and pre-funded warrants for 230,000 shares at $5.9999 each, with each pre-funded warrant exercisable for one share at an exercise price of $0.0001 and subject to a 9.99% beneficial ownership cap.
In the concurrent private placement, the company will issue ordinary warrants for up to 670,000 shares, exercisable immediately at $6.00 per share and expiring on September 16, 2030. These ordinary warrants and the underlying shares are offered under a private placement exemption, with the company obligated to register the warrant shares on Form F-3 as soon as practicable. A.G.P./Alliance Global Partners is acting as exclusive placement agent, earning a 7.0% placement fee, a 1.0% management fee, and up to $50,000 in expense reimbursement. The company agreed to 60-day restrictions on additional equity issuances and variable rate transactions, subject to specified exceptions.